Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01513681 · ClinicalTrials.gov registry record · Phase 1

Bioequivalence Study for Lamotrigine Tablets 200 mg Under Fed Condition

A Phase 1 study of Healthy, sponsored by Dr. Reddy's Laboratories Limited.

Completed
Registry status
Phase 1
Development phase
20
Enrollment target
1
Study location

NCT01513681 is a Phase 1 study of Healthy that has completed, run by Dr. Reddy's Laboratories Limited. The registered enrollment target is 20 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01513681, a Phase 1 study of Healthy, has completed, sponsored by Dr. Reddy's Laboratories Limited.

COMPLETED
Registry status
Phase 1
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

This is an single dose,two-way, crossover, oral bioequivalence study.

Conditions Studied

Interventions

  • DRUG Lamotrigine
  • DRUG Lamictal®

Study Locations (1)

North Carolina

  • AAI Clinic - Quadrangle Drive

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2002-11
Est. Completion 2002-11
Phase Phase 1

Sponsor

Dr. Reddy's Laboratories Limited

52 total trials

What the Registry Record Tells You About NCT01513681

The ClinicalTrials.gov registry entry for NCT01513681 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (97% lower). The listed sponsor is Dr. Reddy's Laboratories Limited, which has 52 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Lamotrigine is the first listed.

NCT01513681 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT01513681 about?

NCT01513681 is a clinical study titled "Bioequivalence Study for Lamotrigine Tablets 200 mg Under Fed Condition". This is an single dose,two-way, crossover, oral bioequivalence study.

What is the current status of trial NCT01513681?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2002-11. Estimated completion is 2002-11.

What conditions does trial NCT01513681 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT01513681?

The interventions under investigation include: Lamotrigine (DRUG), Lamictal® (DRUG).

Who is sponsoring clinical trial NCT01513681?

This trial is sponsored by Dr. Reddy's Laboratories Limited, which has 52 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01513681 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.